Register Login

Ovid Therapeutics Inc (OVID)

(10% Negative) OVID THERAPEUTICS INC. (OVID) Announces Delay in Pharmacokinetics Trials for OV350 were as predicted Due to Geopolitical Situation, Regulatory Process, Safety Review

Full text
Register to leave comments
  • News bot Dec. 18, 2025, 1:41 p.m.

    📋 OVID THERAPEUTICS INC. (OVID) - Clinical Trial Update

    Filing Date: 2025-12-18

    Accepted: 2025-12-18 08:39:41

    Event Type: Clinical Trial Update

    Event Details:

    Ovid Therapeutics Inc (OVID) Announces Clinical Trial Update Ovid Therapeutics Inc (OVID) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Pharmacokinetics, submission
    • Diseases/Conditions: OV350 were as predicted, humans
    • Clinical Stage: Phase 1, clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Regulatory Process
    • Collaboration: Ovid Therapeutics Inc.
    • Updated Timeline: December 18, 2025, Q1 2026
      • targeting restoration of excitatory/inhibitory balance in the brain, which may offer therapeutic benefit across multiple neurological and neuropsychiatric disorders. About OV350 OV350 is a first-in-class, investigational direct activator of KCC2, the neuron-specific chloride transporter that restores inhibitory signaling and helps rebalance hyperexcitable neural circuits. Data from this tool program is informative in establishing safety, tolerability, pharmacokinetics and pharmacodynamic properties of this new mechanism of action for the brain. About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions and symptoms caused by excess neural excitability. Ovid is advancing a pipeline of novel targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; and is developing OV4071

    🔬 Clinical Development Pipeline (OVID THERAPEUTICS INC.):

    Product Type Development Stage Therapeutic Area Source
    Comparator App + Treatment as Usual (TAU) DEVICE Approved Suicidal Ideation ClinicalTrials.gov
    OTX-207 DEVICE Approved Suicidal Ideation ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Ovid Therapeutics Inc
    • CIK: 0001636651
    • Ticker Symbol: OVID
    • Period End Date: 2025-12-18
    • Document Type: 8-K

Search

News categories